Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
What is already known about this subject
Gastric upset is a common side effect of nilotinib therapy, and calcium carbonate is frequently used concomitantly, either as antacid or as calcium supplementation. With the increasing number of oral agents in cancer therapy, oral drug–drug interactions are becoming more relevant. Nilotinib has already been shown to be absorbed to a much lesser extent when co-administered with proton pump inhibitors. Because exposure to sub-therapeutic concentrations of anticancer drugs such as nilotinib may result in selection of resistant clones and ultimately relapse, we studied the effect of a calcium carbonate supplement (Tums Ultra 1000®) on nilotinib pharmacokinetics.
What this study adds
Calcium carbonate may be co-administered with nilotinib without significantly affecting the pharmacokinetics of nilotinib and potentially impacting efficacy.
Nilotinib is a second-generation oral tyrosine kinase inhibitor with superior efficacy compared with imatinib mesylate in the treatment for chronic phase chronic myelogenous leukemia. Calcium carbonate is commonly used as a source of calcium supplementation or as antacid to ameliorate the gastrointestinal side effects associated with nilotinib, which could have unknown effects on nilotinib absorption. The purpose of this study was to provide information on the effect of calcium carbonate on the PK of nilotinib in healthy volunteers.
Healthy subjects were enrolled in a two-period, open-label, single-institution, randomized, cross-over, fixed-schedule study. In one period, each subject received 400 mg of nilotinib p.o. In the other period, 4,000 mg of calcium carbonate (4 X Tums Ultra 1000®) was administered p.o. 15 min prior to the nilotinib dose. Plasma samples were collected at specified timepoints, concentrations of nilotinib were quantitated by LC–MS, and data were analyzed non-compartmentally.
Eleven subjects were evaluable. Calcium supplementation did not significantly affect nilotinib pharmacokinetic parameters including area under the plasma concentration versus time curve (18.4 μg/mL h alone vs. 16.9 μg/mL h with calcium carbonate, p = 0.83; 80 % power); maximum plasma concentration (C max) (0.670 μg/mL alone vs. 6.18 μg/mL with calcium carbonate, p = 0.97); or half-life (18.9 h alone vs. 17.2 h with calcium carbonate, p = 0.18).
Our results indicate that the use of calcium carbonate does not significantly affect nilotinib pharmacokinetics.
- Saglio, G, Kim, DW, Issaragrisil, S, Coutre, P, Etienne, G, Lobo, C, Pasquini, R, Clark, RE, Hochhaus, A, Hughes, TP, Gallagher, N, Hoenekopp, A, Dong, M, Haque, A, Larson, RA, Kantarjian, HM (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362: pp. 2251-2259 CrossRef
- Kantarjian, HM, Hochhaus, A, Saglio, G, De, SC, Flinn, IW, Stenke, L, Goh, YT, Rosti, G, Nakamae, H, Gallagher, NJ, Hoenekopp, A, Blakesley, RE, Larson, RA, Hughes, TP (2011) Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 12: pp. 841-851 CrossRef
- Cho, JH, Kim, KM, Kwon, M, Kim, JH, Lee, J (2011) Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs 30: pp. 2008-2014 CrossRef
- Sawaki, A, Nishida, T, Doi, T, Yamada, Y, Komatsu, Y, Kanda, T, Kakeji, Y, Onozawa, Y, Yamasaki, M, Ohtsu, A (2011) Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer 117: pp. 4633-4641 CrossRef
- Ravaud, A, Bello, CL (2011) Exposure-response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice. Anticancer Drugs 22: pp. 377-383 CrossRef
- Larson, RA, Druker, BJ, Guilhot, F, O’Brien, SG, Riviere, GJ, Krahnke, T, Gathmann, I, Wang, Y (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111: pp. 4022-4028 CrossRef
- Demetri GD, Wang Y, Wehrle E, Blanke C, Joensuu H, von Mehren M (2008) Correlation of imatinib plasma levels with clinical benefit in patients (Pts) with unresectable/metastatic gastrointestinal stromal tumors (GIST). In: ASCO gastrointestinal cancers symposium
- Kantarjian, H, Giles, F, Wunderle, L, Bhalla, K, O’Brien, S, Wassmann, B, Tanaka, C, Manley, P, Rae, P, Mietlowski, W, Bochinski, K, Hochhaus, A, Griffin, JD, Hoelzer, D, Albitar, M, Dugan, M, Cortes, J, Alland, L, Ottmann, OG (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354: pp. 2542-2551 CrossRef
- Radimer, K, Bindewald, B, Hughes, J, Ervin, B, Swanson, C, Picciano, MF (2004) Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999–2000. Am J Epidemiol 160: pp. 339-349 CrossRef
- Straub, DA (2007) Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutr Clin Pract 22: pp. 286-296 CrossRef
- Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, KM U, Staten AM, Pazdur R (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8:935–942
- Parise, RA, Egorin, MJ, Christner, SM, Shah, DD, Zhou, W, Beumer, JH (2009) A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum. J Chromatogr B Analyt Technol Biomed Life Sci 877: pp. 1894-1900 CrossRef
- Campos, DR, Vieira, NR, Bernasconi, G, Barros, FA, Meurer, EC, Marchioretto, MA, Coelho, EC, Calafatti, SA, Sommer, C, Couto, JM, Buranello, S, Silva, AR, Amarante, AR, Abib, E, Junior, JP (2007) Bioequivalence of two enteric coated formulations of pantoprazole in healthy volunteers under fasting and fed conditions. Arzneimittelforschung 57: pp. 309-314
- Sparano, BA, Egorin, MJ, Parise, RA, Walters, J, Komazec, KA, Redner, RL, Beumer, JH (2009) Effect of antacid on imatinib absorption. Cancer Chemother Pharmacol 63: pp. 525-528 CrossRef
- Yin, OQ, Gallagher, N, Fischer, D, Demirhan, E, Zhou, W, Golor, G, Schran, H (2010) Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Pharmacol 50: pp. 960-967 CrossRef
- Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers
Cancer Chemotherapy and Pharmacology
Volume 72, Issue 5 , pp 1143-1147
- Cover Date
- Print ISSN
- Online ISSN
- Springer Berlin Heidelberg
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute, Hillman Research Pavilion, Room G27D, 5117 Centre Avenue, Pittsburgh, PA, 15213-1863, USA
- 2. Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA
- 3. Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, 15213, USA
- 4. Clinical Research Services, University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213, USA
- 5. Investigational Drug Service, UPMC Cancer Centers, Pittsburgh, PA, 15213, USA
- 6. Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA
- 7. Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, 15213, USA